AndroGel Pharmacogenomics: How Genetic Variability Shapes Testosterone Gel Response

How AndroGel Works at the Molecular Level

Testosterone gel delivers the native androgen through a hydroalcoholic vehicle that acts as a permeation enhancer across the stratum corneum. Once testosterone partitions into the dermis, it enters the microvasculature and distributes systemically 1. The drug itself is a pro-hormone. Tissue-level enzymes convert it into two principal active metabolites: 5-alpha reductase (encoded by SRD5A2) reduces testosterone to dihydrotestosterone (DHT), while aromatase (encoded by CYP19A1) converts it to estradiol.

Both metabolites bind distinct nuclear receptors and trigger different downstream gene transcription programs. DHT drives androgenic effects in skin, hair follicles, and the prostate. Estradiol mediates bone mineral accrual and feedback on the hypothalamic-pituitary axis. The ratio of these conversions is not fixed. It depends on the enzyme expression levels encoded by each patient's genome, which is why two men using the same 50 mg daily dose of AndroGel can show markedly different serum testosterone, DHT, and estradiol profiles 2.

The FDA label for AndroGel 1.62% notes that steady-state serum testosterone concentrations are achieved within approximately 24 hours due to the skin depot effect 3. Application to the shoulders and upper arms produces more consistent absorption than chest application. Even with this optimized site, the coefficient of variation for Cmax across individuals exceeds 50% in pharmacokinetic studies, pointing to a strong role for biological, not just behavioral, sources of variability.

The Androgen Receptor CAG Repeat: Your Sensitivity Dial

The androgen receptor gene on chromosome Xq11-12 contains a polymorphic CAG trinucleotide repeat in exon 1, and the length of this repeat inversely correlates with receptor transcriptional activity 4. Normal repeat length ranges from about 10 to 35. Men with shorter repeats (below 20) mount a stronger transcriptional response per unit of bound testosterone. Men with longer repeats need higher circulating testosterone to achieve the same degree of androgen-dependent gene activation.

This matters for TRT. A 2012 analysis in the Journal of Clinical Endocrinology & Metabolism found that AR CAG repeat length predicted symptom response to testosterone replacement independently of achieved serum testosterone concentration 5. Men with CAG repeats above 24 reported less improvement in libido and energy at the same target testosterone range compared to men with shorter repeats.

The clinical implication is straightforward. A man whose serum testosterone reaches 500 ng/dL on AndroGel but carries a long CAG repeat may experience the functional equivalent of a man at 350 ng/dL with a short repeat. This could explain a frustrating clinical scenario: the lab value looks adequate, yet the patient still reports fatigue or low drive. "CAG repeat length should be considered a modifier of the clinical response to testosterone therapy," wrote Zitzmann et al. in their pharmacogenetic review of androgen action 6.

SRD5A2 Polymorphisms and the DHT Conversion Rate

The SRD5A2 gene encodes steroid 5-alpha reductase type 2, the enzyme responsible for converting testosterone to the more potent androgen DHT in target tissues including the prostate, skin, and genital tissue. Several single-nucleotide polymorphisms (SNPs) alter enzyme kinetics. The V89L variant (rs523349) reduces 5-alpha reductase activity by approximately 30%, resulting in lower DHT-to-testosterone ratios 7.

Population frequency varies substantially. The V89L variant is present in roughly 30% of men of European ancestry but in over 50% of men of East Asian ancestry 7. For a man on AndroGel carrying the homozygous V89L genotype, the expected DHT rise will be blunted relative to a wild-type carrier even if serum total testosterone levels match. This has practical downstream effects: DHT is the primary androgen driving libido improvements, sebaceous gland activity, and prostate growth during TRT.

At the opposite end, the A49T variant increases enzyme activity and has been associated with higher DHT levels and a possibly increased prostate cancer risk in some case-control studies 8. Men who carry this gain-of-function variant and use topical testosterone may generate disproportionately high DHT relative to their total testosterone, a detail relevant for PSA monitoring.

Neither variant changes the recommended starting dose of AndroGel. But they do affect the metabolite profile that results from that dose. A prescriber who sees a high DHT-to-testosterone ratio on routine labs might consider the patient's SRD5A2 genotype before assuming non-adherence or an absorption issue.

UGT2B17: The Gene That Controls Testosterone Clearance

Uridine diphosphate glucuronosyltransferase 2B17 (UGT2B17) is the primary phase II enzyme conjugating testosterone to testosterone glucuronide for renal excretion. A common copy-number variant, the UGT2B17 deletion polymorphism, eliminates the gene entirely on one or both chromosomes 9.

About 10% of men of European descent carry a homozygous deletion (del/del), compared to roughly 67% of Korean men in one large survey 9. Men with the del/del genotype clear testosterone glucuronide more slowly, leading to higher circulating testosterone and a longer effective half-life per applied dose. This finding is well established in anti-doping research, where the UGT2B17 deletion is known to produce false-negative results on the urinary T/E ratio test 10.

For TRT, the consequence is clinically meaningful. A del/del patient starting AndroGel at 40.5 mg daily may reach supratherapeutic trough levels where an ins/ins patient on the same dose sits mid-range. Monitoring with a 14-day post-initiation serum testosterone draw (as the FDA label recommends) should catch this, but knowing the UGT2B17 genotype in advance could enable a lower starting dose. Dr. Jenny Lundgren and colleagues observed that "the UGT2B17 deletion genotype is one of the strongest genetic predictors of testosterone disposition and should be incorporated into pharmacogenomic models for androgen therapy" 10.

CYP19A1 and Estrogen Conversion on TRT

Aromatase, encoded by CYP19A1 on chromosome 15q21, catalyzes the conversion of testosterone to estradiol in adipose tissue, brain, bone, and other sites. Over 100 SNPs have been catalogued in the CYP19A1 locus. The tetranucleotide (TTTA)n repeat in intron 4 and the 3'-UTR SNP rs10046 are the best studied in clinical endocrinology 11.

Men who carry high-activity CYP19A1 alleles aromatize a larger fraction of exogenous testosterone to estradiol. On AndroGel, this manifests as a rising estradiol level that can exceed 40-50 pg/mL and contribute to gynecomastia, water retention, and negative mood effects. A study of 120 hypogonadal men receiving testosterone replacement found that those in the highest quartile for estradiol had a 3.5-fold greater risk of developing breast tenderness within 6 months 12.

Adiposity amplifies the genetic signal because CYP19A1 expression is proportional to fat mass. A man with both a high-activity aromatase genotype and a BMI above 30 represents a compounding risk for estrogen-related side effects on topical testosterone. Clinicians sometimes respond by adding an aromatase inhibitor such as anastrozole 0.5 mg twice weekly, though the Endocrine Society's 2018 guideline noted that routine anastrozole co-prescription lacks long-term safety data and should not be standard practice 13.

What the T-Trials Revealed About Individual Variability

The Testosterone Trials (TTrials) enrolled 790 men aged 65 years and older with serum testosterone concentrations below 275 ng/dL and symptoms of hypogonadism 14. Participants applied AndroGel 1% daily with dose titration targeting serum testosterone between 500 and 800 ng/dL.

Despite protocolized titration, the range of achieved testosterone levels was broad. Some men required only 2.5 g daily gel to maintain the target window, while others needed the maximum 10 g daily. The TTrials were not designed as a pharmacogenomic study, so genotype data for AR, SRD5A2, UGT2B17, or CYP19A1 were not systematically reported. Still, the 4-fold dose range required to reach similar serum targets strongly implicates genetic variability in absorption and metabolism.

The TTrials also documented that testosterone gel improved sexual function (as measured by the PDQ-Q4 score, with a mean increase of 0.58 activities per month vs. placebo), improved mood on the PHQ-9 scale, and increased 6-minute walk distance by a modest 6.1 meters 14. The magnitude of benefit varied considerably across individuals, and secondary analyses suggested that baseline testosterone level alone did not fully predict who would respond best.

This observation supports the pharmacogenomic hypothesis: response heterogeneity in the TTrials likely reflects, at least in part, the combined influence of receptor sensitivity (AR CAG), metabolic enzyme activity (SRD5A2, CYP19A1), and clearance rate (UGT2B17).

Skin-Level Pharmacogenomics: Why Absorption Differs

Beyond systemic metabolism, genetic variation affects how much testosterone actually enters the bloodstream from the application site. The stratum corneum's barrier function depends on lipid composition, corneocyte structure, and aquaporin expression, all of which carry heritable variation 15.

Filaggrin (FLG) loss-of-function mutations, present in 8-10% of Northern European populations, disrupt the skin's lipid barrier and may increase transdermal drug permeation. While no published study has directly measured the effect of FLG variants on testosterone gel absorption, the pharmacokinetic principle is established for other transdermal drugs. Men with eczema-prone skin (often FLG-related) should be monitored carefully during the first weeks of AndroGel therapy, as they may absorb more testosterone than expected.

Sweating dilutes the gel reservoir. Eccrine gland density is partially heritable and varies roughly 2-fold across individuals. Applying AndroGel after a cool shower, as the label recommends, reduces this variable, but it does not eliminate it. Body hair density, another heritable trait, also modifies absorption by trapping gel on hair shafts rather than allowing direct skin contact.

Toward Pharmacogenomic-Guided TRT Dosing

No FDA-approved pharmacogenomic test currently exists specifically for testosterone therapy. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has not yet issued a guideline for androgens. But the pharmacogenomic evidence base for testosterone is arguably stronger than for some drugs that already have CPIC guidelines.

A practical near-term approach would combine pre-treatment genotyping of AR CAG repeat length and UGT2B17 copy number with standard lab monitoring. Men with long AR CAG repeats could be counseled that target testosterone levels may need to be higher than textbook ranges to achieve symptomatic relief. Men with UGT2B17 del/del genotype could begin at the lowest available dose (20.25 mg for AndroGel 1.62%) and titrate cautiously.

The Endocrine Society's 2018 guideline recommends measuring serum testosterone 2 to 4 weeks after starting or changing a dose, then at 3 months, 6 months, and annually thereafter 13. Until pharmacogenomic panels become standard, this serial monitoring protocol remains the primary tool for managing the genetic variability that shapes every patient's response to AndroGel. Men with unexplained poor response or unexpected side effects at guideline-concordant serum levels should be considered candidates for targeted genotyping of AR, SRD5A2, UGT2B17, and CYP19A1.